Andrzej Stanczak

Andrzej Stanczak


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MSMarta Szumilak
Marta Szumilak
AWAnna Wiktorowska-Owczarek
Anna Wiktorowska-Owczarek
ASAndrzej Stanczak
Andrzej Stanczak
Despite enormous progress in the treatment of many malignancies, the development of cancer resistance is still an important reason for cancer chemotherapy failure. Increasing knowledge of cancers’ molecular complexity and mechanisms of their resistance to anticancer drugs, as well as extensive clinical experience, indicate that an effective fight against cancer requires a multidimensional approach. Multi-target chemotherapy may be achieved using drugs combination, co-delivery of medicines, or designing hybrid drugs. Hybrid drugs simultaneously targeting many points of signaling networks and various structures within a cancer cell have been extensively explored in recent years. The single hybrid agent can modulate multiple targets involved in cancer cell proliferation, possesses a simpler pharmacokinetic profile to reduce the possibility of drug interactions occurrence, and facilitates the process of drug development. Moreover, a single medication is expected to enhance patient compliance due to a less complicated treatment regimen, as well as a diminished number of adverse reactions and toxicity in comparison to a combination of drugs. As a consequence, many efforts have been made to design hybrid molecules of different chemical structures and functions as a means to circumvent drug resistance. The enormous number of studies in this field encouraged us to review the available literature and present selected research results highlighting the possible role of hybrid drugs in overcoming cancer drug resistance.

9 February 2007 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
WLWieslawa Lewgowd
Wieslawa Lewgowd
ASAndrzej Stanczak
Andrzej Stanczak

1 July 2006
Verified
Journal Article
Closed access
PBPawel Baranczewski
Pawel Baranczewski
ASAndrzej Stanczak
Andrzej Stanczak
KSKathrin Sundberg
Kathrin Sundberg
RSRichard Svensson
Richard Svensson
AWAsa Wallin
Asa Wallin
HPHans Postlind
Hans Postlind

1 July 1994 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
AGAnette Graven
Anette Graven
KJKarl Anker Joergensen
Karl Anker Joergensen
SDSoeren Dahl
Soeren Dahl
ASAndrzej Stanczak
Andrzej Stanczak

18 June 2019 in Molecules
Verified
Journal Article
Open access
PDF file
MSMarta Szumilak
Marta Szumilak
ASAndrzej Stanczak
Andrzej Stanczak
The cinnoline nucleus is a very important bicyclic heterocycle that is used as the structural subunit of many compounds with interesting pharmaceutical properties. Cinnoline derivatives exhibit broad spectrum of pharmacological activities such as antibacterial, antifungal, antimalarial, anti-inflammatory, analgesic, anxiolytic and antitumor activities. Some of them are under evaluation in clinical trials. In the present review, we have compiled studies focused on the biological properties of cinnoline derivatives conducted by many research groups worldwide between 2005 and 2019. Comprehensive and target oriented information clearly indicate that the development of cinnoline based molecules constitute a significant contribution to the identification of lead compounds with optimized pharmacodynamic and pharmacokinetic properties.

1 December 2010 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMarta Szumilak
Marta Szumilak
ASAgata Szulawska-Mroczek
Agata Szulawska-Mroczek
KKKamila Koprowska
Kamila Koprowska
MSMarta Stasiak
Marta Stasiak
WLWieslawa Lewgowd
Wieslawa Lewgowd
MCMalgorzata Czyz
Malgorzata Czyz